Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactococcus casei is a probiotic bacterium that has been investigated for its potential benefits in managing colitis, particularly inflammatory bowel diseases (IBD) such as ulcerative colitis. Scientific interest in L. casei stems from its immunomodulatory effects and its potential to restore gut microbiota balance. Several animal studies have demonstrated that administration of L. casei can reduce inflammation, decrease disease activity, and ameliorate colonic damage in chemically-induced colitis models (e.g., DSS-induced colitis in mice). These effects are attributed to its ability to modulate cytokine production, enhance epithelial barrier function, and suppress pro-inflammatory pathways.

However, clinical evidence in humans is limited. A few small clinical trials and pilot studies have examined the efficacy of L. casei (often as part of multi-strain probiotic formulations) in patients with ulcerative colitis. Results suggest some potential benefit in maintaining remission or reducing relapse rates, but findings are inconsistent and studies are generally underpowered or lack proper controls. Major clinical guidelines do not currently recommend L. casei as a standard treatment for colitis due to insufficient high-quality evidence.

In summary, while there are plausible mechanisms and promising preclinical data, the clinical evidence is not robust. The rating of 2 reflects preliminary scientific support, but further larger and well-controlled human trials are needed to establish its efficacy for colitis.

More about Lactococcus casei
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Lactococcus casei

Products containing Lactococcus casei